<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>Firocoxib on aqueous humor prostaglandin E2  levels for controlling experimentallyinduced breakdown of blood-aqueous barrier in healthy and Toxoplasma gondii-seropositive cats</title>
  </titleInfo>
  <name type="personal">
    <namePart>Schroder, Deise Cristine</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Stocco, Matias Bassinello</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Isoton, Deborah de Arruda</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Silva, Carla Patricia Amarante e</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Braga, Ísis Assis</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Silva, Érica Pereira da</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Maciel, Camila do Espírito Santo</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Maruyama, Fernanda Harumi</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Nakazato, Luciano</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Aguiar, Daniel Moura de</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Mendonça, Adriane Jorge</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Ribeiro, Alexandre Pinto</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <typeOfResource>text</typeOfResource>
  <genre authority="marc">periodical</genre>
  <genre authority="marc">abstract or summary</genre>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">bl.</placeTerm>
    </place>
    <issuance>continuing</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <abstract>

ABSTRACT - This study aimed to evaluate the effects of firocoxib for controlling experimentally-induced breakdown of the bloodaqueous barrier in healthy and Toxoplasma gondii-seropositive cats. Thirty two cats with no ocular abnormalities were used. Groups (n=8/each) were formed with healthy cats that received 5mg g-1 of oral firocoxib (FH) or no treatment (CH) on day 0; seropositive cats for anti-T. gondii specific immunoglobulin G (IgG) were grouped (n=8/each) and treated in a similar fashion (FT and CT). On day 1, cats of all groups received the same treatment protocol, and 1h later, aqueocentesis was performed under general anesthesia (M0). Following 1h, the same procedure was repeated (M1). Quantitation of aqueous humor total protein and prostaglandin E2  (PGE2 ) were determined. Aqueous samples of seropositive cats were tested for anti-T. gondii specific IgG. In M0, aqueous samples of CT showed a significantly higher concentration of PGE2  in comparison with other groups (P&lt;0.05). In all groups, PGE2  concentration increased significantly from M0 to M1 (P=0.001). PGE2  values did not change significantly between groups in M1 (P=0.17). Anti-T. gondii specific IgG were reported only in samples of M1, and aqueous titers did not change significantly between FT and CT (P=0.11). Although we have observed that aqueous humor PGE2  levels were significantly higher in cats of CT group during M0, such increase was not able to break the blood-aqueous barrier and cause anterior uveitis. Firocoxib did not prevent intraocular inflammation after aqueocentesis, in healthy and toxoplasmosis-seropositive cats.

Key words: aqueous humor, intraocular inflammation, NSADs, toxoplasmosis.</abstract>
  <abstract>

RESUMO - Objetivou-se avaliar a eficácia do firocoxib no controle da quebra da barreira hematoaquosa experimentalmente induzida em gatos saudáveis e com sorologia positiva para toxoplasmose. Para tanto, utilizaram-se trinta e dois gatos sem alterações oculares, alocados em grupos (n=8/cada) compostos por gatos saudáveis que receberam tratamento prévio com 5mg g-1 de firocoxib oral (HF) ou sem nenhum tratamento (CH) no dia 0, e por gatos com sorologia positiva para toxoplasmose tratados de maneira similar (FT e CT). No dia 1, os gatos de todos os grupos receberam o mesmo protocolo de tratamento do dia anterior e, 1h depois, foram submetidos à paracentese da câmara anterior sob anestesia geral (M0). Após 1h, realizou-se nova paracentese (M1). Mediante a colheita de humor aquoso (M0 e M1), quantificaramse os valores de proteína total e prostaglandina E2  (PGE2) das amostras. As amostras dos gatos com sorologia positiva para toxoplasmose foram também testadas para anticorpos anti-T. gondii IgG específicos. Em M0, as amostras de humor aquoso de CT apresentaram concentração de PGE2  significativamente superior aos demais grupos (P&lt;0,05). Em todos os grupos, a concentração de PGE2 aumentou significativamente de M0 para M1 (P=0,001), no entanto, não houve diferença significativa entre os grupos em M1 (P=0,17). Anticorpos anti-T. gondii IgG específicos foram encontrados somente em amostras de M1, e os títulos não diferiram significativamente entre FT e CT (P=0,11). Valores de PGE2  significativamente superiores no CT durante M0 não foram capazes de induzir a quebra da barreira hematoaquosa e causar uveíte anterior nos gatos deste estudo. O firocoxib, por sua vez, não foi capaz de prevenir a quebra da barreira hematoaquosa após realização de paracente na câmara anterior em gatos saudáveis e com sorologia positiva para toxoplasmose.

Palavras-chave: humor aquoso, inflamação intraocular, AINEs, toxoplasmose.</abstract>
  <note>Publicação on-line; 23 ref.; Sumaries (En, Pt)</note>
  <subject>
    <topic>GATO</topic>
  </subject>
  <subject>
    <topic>TOXOPLASMA</topic>
  </subject>
  <subject>
    <topic>DOENÇA ANIMAL</topic>
  </subject>
  <subject>
    <topic>VETERINÁRIA</topic>
  </subject>
  <relatedItem type="host">
    <titleInfo>
      <title>Ciência Rural (Brazil)</title>
    </titleInfo>
    <originInfo>
      <publisher>Santa Maria-RS Universidade Federal de Santa Maria - Centro de Ciências Rurais 1991</publisher>
    </originInfo>
    <identifier>2024-1179</identifier>
    <identifier type="issn">0103-8478</identifier>
    <identifier type="local">BR2024001341</identifier>
    <part>
      <text>v. 46(6) p. 1053-1058; (2016)</text>
    </part>
  </relatedItem>
  <identifier type="uri">https://www.scielo.br/j/cr/a/sDbFYqftN8CgRnYKQtxkjLk/?format=pdf&amp;lang=en</identifier>
  <location>
    <url>https://www.scielo.br/j/cr/a/sDbFYqftN8CgRnYKQtxkjLk/?format=pdf&amp;lang=en</url>
  </location>
  <recordInfo>
    <recordContentSource authority="marcorg">BR-BrBNA</recordContentSource>
    <recordCreationDate encoding="marc">240819</recordCreationDate>
    <recordChangeDate encoding="iso8601">20240819121927.0</recordChangeDate>
    <languageOfCataloging>
      <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
    </languageOfCataloging>
  </recordInfo>
</mods>
